Publications by authors named "M D Danese"
Objectives: This study describes clinical characteristics and management strategies for patients with factor Xa (FXa) inhibitor-related traumatic non-intracranial bleeds who were treated with andexanet alfa or four-factor prothrombin complex concentrate (4F-PCC).
Methods: An observational cohort study (ClinicalTrials.gov Identifier: NCT05548777) was conducted using electronic health records from 354 US hospitals.
Effect of Chemotherapy and Surgery Timing on Mortality in Upper and Lower Extremity Osteosarcoma.
J Natl Cancer Inst
September 2024
Article Synopsis
- * Results showed a 5-year survival rate of 74% for the Surgery First group compared to 67% for the Neoadjuvant First group, suggesting a 6.9% survival advantage for the Surgery First approach.
- * The findings indicate weak evidence for neoadjuvant therapy, warranting further research into the timing of surgery and chemotherapy in osteosarcoma treatment.
Introduction: The treatment landscape of small cell lung cancer (SCLC) is evolving. Evidence generated from administrative claims is needed to characterize real-world SCLC patients. However, the current ICD-10 coding system cannot distinguish SCLC from non-small cell lung cancer (NSCLC).
View Article and Find Full Text PDF